



Raising Awareness

RSV Week

3-7 November 2025

Increasing awareness of RSV, a common virus that can cause severe respiratory infections, especially in young children and the elderly.

www.hvivo.com





RSV Insights

1. Almost Every Child Gets RSV by Age 2

RSV (Respiratory Syncytial Virus) is one of the most common causes of respiratory infections in infants and young children — almost all children are infected by age 2.

2. RSV Can Cause Serious Lung Infections

Most RSV cases are mild, but it can lead to bronchiolitis or pneumonia, especially in babies, older adults, or those with weakened immune systems.



RSV Insights

3. RSV Causes 100,000 Child Deaths Globally Each Year

RSV is responsible for an estimated 100,000 deaths annually among children under 5, with nearly half of those deaths occurring in infants younger than 6 months.

4. Preventive Protection Is Now Available

Recent medical advances have introduced RSV vaccines for older adults and monoclonal antibody protection for infants, offering new ways to reduce severe illness.

RSV Week – Raising Awareness



How **hVIVO** can Help

At hVIVO, we provide comprehensive end-to-end support for the development and evaluation of RSV vaccines and antiviral therapeutics through our controlled human infection models and specialist laboratory services.



RSV Week – Raising Awareness

hVIVO

How **hVIVO** can Help

✓ Successfully developed a
RSV human challenge model

✓ Phase I, Phase II & RSV
Vaccine Studies

✓ Excellent patient
recruitment to run
studies

✓ Laboratory Services

✓ Sample Transport
Matrix (STM)





Our RSV Pathogens available

RSV-A

Memphis 37

RSV-B

London 2023

RSV-A

2024 Isolate

In development

Successful Case Studies:

hVIVO has announced multiple contracts with “top-tier” pharmaceutical or biotech clients to use their RSV human challenge model for both vaccines & antivirals.

In 2022, hVIVO ran the Pfizer Phase 2a proof-of-concept study for their RSVpreF candidate, which later gained FDA Fast-Track & hit the market in 2023.

Earlier this year, we reported of the successful positive results from our client Shiongi, with their positive results for the Phase 2a RSV anti-infective human challenge trial.

RSV Week – Raising Awareness



Industry Leader in Virology and Immunology Laboratory Services

With over 85,000 samples processed annually, a biobank of over 500,000 samples, and a wealth of experience, we are the right partner for your clinical trial support.

Our RSV Dedicated Services include...

qPCR

Precise target quantification for use in either preclinical or clinical samples

Integrated Cyclers–qicPCR

Designed for precise detection of respiratory viruses





Sample Transport Matrix (STM)

We can validate commercially available sample transport matrices to ensure they meet the specific needs for your clinical program.

Proprietary RSV stabilisation matrix

Designed to maintain RSV sample integrity during storage and shipment.

- Validated for long-term stability at -80°C
- Compatible with flexible storage conditions
- Ensures reliable viral load measurement
- Ideal for RSV field trials and human challenge studies



RSV Week – Raising Awareness



Raising Awareness

Learn More

Repost our post to spread the word on RSV

hVIVO has a wealth of experience and knowledge on RSV. **Contact us today** to learn how we can support you on your journey to help tackle this disease.

www.hvivo.com

